Chlorine in PDB 5zv2: Fgfr-1 in Complex with Ligand Lenvatinib

All present enzymatic activity of Fgfr-1 in Complex with Ligand Lenvatinib:
2.7.10.1;

The structure of Fgfr-1 in Complex with Ligand Lenvatinib, PDB code: 5zv2 was solved by M.Matsuki, T.Hoshi, Y.Yamamoto, M.Ikemori-Kawada, Y.Minoshima, Y.Funahashi, J.Matsui, with X-Ray Crystallography technique. A brief refinement statistics is given in the table below:

Resolution Low / High (Å)	100.65 / 2.86
Space group	C 1 2 1
Cell size a, b, c (Å), α, β, γ (°)	210.214, 57.464, 65.955, 90.00, 106.75, 90.00
R / Rfree (%)	21.3 / 26.9

The binding sites of Chlorine atom in the Fgfr-1 in Complex with Ligand Lenvatinib (pdb code 5zv2). This binding sites where shown within 5.0 Angstroms radius around Chlorine atom.
In total 2 binding sites of Chlorine where determined in the Fgfr-1 in Complex with Ligand Lenvatinib, PDB code: 5zv2:
Jump to Chlorine binding site number: 1; 2;

Chlorine binding site 1 out of 2 in the Fgfr-1 in Complex with Ligand Lenvatinib


Mono view


Stereo pair view

A full contact list of Chlorine with other atoms in the Cl binding site number 1 of Fgfr-1 in Complex with Ligand Lenvatinib within 5.0Å range: probe atom residue distance (Å) B Occ A:Cl801 b:98.6 occ:1.00 CL A:LEV801 0.0 98.6 1.0 C19 A:LEV801 1.7 60.6 1.0 C20 A:LEV801 2.7 70.0 1.0 C18 A:LEV801 2.7 70.6 1.0 N23 A:LEV801 2.9 84.6 1.0 CB A:LYS514 3.6 80.0 1.0 OE2 A:GLU531 3.7 93.8 1.0 CD A:LYS514 3.8 87.7 1.0 CG2 A:VAL561 3.9 66.2 1.0 C21 A:LEV801 4.0 75.5 1.0 C17 A:LEV801 4.0 63.7 1.0 C24 A:LEV801 4.0 87.0 1.0 CG1 A:VAL561 4.1 68.4 1.0 CG A:LYS514 4.3 88.6 1.0 C22 A:LEV801 4.5 63.7 1.0 N26 A:LEV801 4.7 79.8 1.0 CB A:VAL561 4.7 61.3 1.0 N A:LYS514 4.7 72.6 1.0 CA A:LYS514 4.7 68.8 1.0 O25 A:LEV801 4.8 69.5 1.0 O A:VAL559 4.8 69.3 1.0 CE A:MET535 4.9 83.3 1.0 CD A:GLU531 4.9 0.7 1.0

Chlorine binding site 2 out of 2 in the Fgfr-1 in Complex with Ligand Lenvatinib


Mono view


Stereo pair view

A full contact list of Chlorine with other atoms in the Cl binding site number 2 of Fgfr-1 in Complex with Ligand Lenvatinib within 5.0Å range: probe atom residue distance (Å) B Occ B:Cl801 b:0.6 occ:1.00 CL B:LEV801 0.0 0.6 1.0 C19 B:LEV801 1.7 71.5 1.0 C20 B:LEV801 2.7 85.8 1.0 C18 B:LEV801 2.7 66.3 1.0 N23 B:LEV801 2.8 97.6 1.0 CG2 B:VAL561 3.5 67.7 1.0 CB B:LYS514 3.6 68.8 1.0 CG1 B:VAL561 3.9 68.6 1.0 C21 B:LEV801 4.0 83.0 1.0 C17 B:LEV801 4.0 69.0 1.0 C24 B:LEV801 4.0 99.1 1.0 CD B:LYS514 4.1 73.2 1.0 CB B:VAL561 4.3 70.6 1.0 OE2 B:GLU531 4.4 82.5 1.0 CG B:LYS514 4.4 63.4 1.0 N B:LYS514 4.4 77.1 1.0 C22 B:LEV801 4.5 67.5 1.0 O B:VAL559 4.6 67.6 1.0 CA B:LYS514 4.6 81.4 1.0 N26 B:LEV801 4.7 94.7 1.0 CE B:LYS514 4.7 81.8 1.0 O25 B:LEV801 4.9 95.5 1.0 NZ B:LYS514 4.9 93.1 1.0

M.Matsuki, T.Hoshi, Y.Yamamoto, M.Ikemori-Kawada, Y.Minoshima, Y.Funahashi, J.Matsui. Lenvatinib Inhibits Angiogenesis and Tumor Fibroblast Growth Factor Signaling Pathways in Human Hepatocellular Carcinoma Models. Cancer Med V. 7 2641 2018.
ISSN: ISSN 2045-7634
PubMed: 29733511
DOI: 10.1002/CAM4.1517